Eli Lilly’s Q4 Revenue Jumps 43% on $11.7B GLP-1 Sales
Fourth-quarter revenue rose 43% year-over-year, driven by GLP-1 drugs Mounjaro and Zepbound, which combined for $11.7 billion in sales and accounted for over 60% of total revenue. The stock trades at a P/E of 46, raising concerns that intensifying GLP-1 competition may pressure its valuation.
1. Fourth-Quarter Revenue Surge
Lilly posted a 43% year-over-year increase in fourth-quarter revenue, reflecting strong demand for its flagship products. This growth rate significantly outpaced overall industry averages for large-cap pharmaceuticals during the period.
2. GLP-1 Sales Breakdown
The company’s GLP-1 therapies Mounjaro and Zepbound generated a combined $11.7 billion, representing over 60% of total quarterly revenue. This concentration underscores the blockbuster status of Lilly’s weight-loss and diabetes franchises.
3. Valuation and Competitive Risks
Lilly currently trades at a P/E ratio of 46, reflecting high investor expectations for continued GLP-1 growth. However, mounting competition from both established drugmakers and new entrants raises the risk of margin compression and revenue deceleration in the near term.